cilostazol Capsules 50 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Manufacturer #9692
This pharmaceutical company focuses on developing and manufacturing innovative medicines across a range of therapeutic areas, including cardiovascular diseases, oncology, and nephrology. They have established core competencies in research & development, production, and sales, particularly for "four high and one anti-resistance" conditions (high blood sugar, hypertension, hyperlipidemia, high uric acid, and anti-tumor). Their product portfolio encompasses prescription medications, likely including insulin injections for diabetes treatment. They hold GMP certifications and product patents, signifying their commitment to quality and innovation. The company operates in key regions like North America and the EU, actively pursuing global commercialization and localization of its products.
Cilostazol is a medication used to treat intermittent claudication in peripheral vascular disease. Suppliers of cilostazol market it in the form of 50mg and 100mg tablets.
The drug was first introduced into the pharmaceutical market in 1999 and has since then become a widely prescribed medication with over a million prescriptions of cilostazol registered yearly in the U.S. alone. The largest manufacturers of cilostazol globally include GlaxoSmithKline, Bristol-Myers Squibb, Bedford Laboratories, Takeda, Novartis, Mylan, Abbot, and Pfizer.
Cilostazol suppliers and distributors market both generic and trade name formulations of the drug. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified cilostazol manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
The retail prices per 56 (100mg) tablets of cilostazol fall into an approximate range of 15,00 EUR to 20,00 EUR.